Merck criticises ‘successive UK governments’ as it cancels King’s Cross development
Merck criticises ‘successive UK governments’ as it cancels King’s Cross development
Copy link
The firm, known as MSD in Europe, said there has been a lack of investment in life sciences.
The U.K. is in the midst of a falling out with big pharma over drug pricing. Merck has walked away from a £1 billion facility in…
Drug companies increasingly frustrated with the Government over surging NHS clawbacks
Its decision comes as the industry says there is a lack of government investment and as the US pressures firms to invest there.
Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears
Drugmaker had stalled large-scale projects in England but has now pledged investment at two sites, announced by Keir Starmer
Merck scraps £1bn expansion in the UK over lack of state investment
How the UK fell out with big pharma
AstraZeneca pauses £200m Cambridge investment
AstraZeneca pauses $270 million investment in Britain
Britain is ‘a terrible place’ to sell medicines, says drug firm executive
